Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

NT 201

Aliases
Botulinum toxin type A (150 kiloDalton), free from complexing proteins, IncobotulinumtoxinA, Incobotulinumtoxin A, NT 201 Placebo (3 other aliases)
Name
DAXXIFY
INN Name
Botulinum Toxin Type A
FDA Approved
Yes

6 clinical trials

3 organizations

8 indications

2 documents

Indication
Essential Tremor
Indication
Spasticity due to Stroke or Traumatic Brain Injury
Indication
Platysmal Band
Indication
Horizontal Forehead Lines
Indication
Glabellar Frown Lines
Indication
Lateral Canthal Lines
Indication
Enlarged Pores
Indication
Sebum Hypersecretion
Clinical trial
Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate the Efficacy and Safety of NT 201 in the Unilateral and Bilateral Treatment of Essential Tremor of the Upper Limb
Status: Completed, Estimated PCD: 2023-04-26
Clinical trial
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Prospective, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 Doses in the Treatment of Platysma Prominence
Status: Completed, Estimated PCD: 2023-10-19
Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Status: Completed, Estimated PCD: 2021-04-15
Clinical trial
A Prospective, Randomized, Double-blind, Multicenter Study to Investigate the Safety and Duration of Effect of Different NT 201 Dose Groups Following the Treatment of Glabellar Frown Lines
Status: Completed, Estimated PCD: 2020-09-10
Clinical trial
A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Exploratory Study to Investigate NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Document
DailyMed Label: DAXXIFY
Organization
Revance Therapeutics, Inc.
Document
DailyMed Label: Dysport
Organization
Galderma Laboratories, L.P.
Organization
Ipsen Biopharmaceuticals, Inc.